The Belfer Research Building
In 2014, Weill Cornell Medical College opened the Belfer Research Building, a state-of-the-art facility that ushers in a new era at the institution for cutting-edge, translational science. The 18-story, $650 million building, made possible through the generosity of numerous donors, nearly doubles Weill Cornell's existing research space and empowers scientists to rapidly translate groundbreaking discoveries into the most advanced patient care.
The 480,000-square-foot building, located at 69th Street and York Avenue, is devoted to translational bench-to-bedside research targeting some of the most formidable health challenges of the 21st century, including cancer, cardiovascular disease, metabolic diseases, neurodegenerative diseases such as Alzheimer's and Parkinson's, children's health, global health and infectious diseases. Its proximity to the adjacent Weill Greenberg Center, the medical college's flagship ambulatory care center at 1305 York Ave. at 70th Street, ensures that breakthroughs made in the laboratory can be quickly and seamlessly applied to patient care as improved treatments and therapies in the clinic. The Belfer Research Building will also serve as a nucleus where physician-scientists, educators, students and researchers from Weill Cornell and around the globe can collaborate on the latest discoveries and research breakthroughs.
In a landmark move that will foster new research collaborations between WCMC and Hunter College, Hunter College has purchased 21,000 square feet of life sciences lab space in the building. This commitment is a highlight of a long-standing partnership begun by the Weill Cornell Clinical and Translational Science Center (CTSC) and Hunter College, a relationship that the National Institutes of Health calls a model for public-private research partnerships.
The Belfer Research Building will also be home to the pioneering Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a new, groundbreaking partnership between Memorial Sloan-Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College. The Tri-I TDI will work to more effectively translate discoveries made in basic science labs into therapeutics. By focusing on the early stages of developing compounds, it hopes to facilitate the conduct of the important "proof of concept" studies that may demonstrate that targeting a specific biologic pathway can favorably alter the course of a disease. The Tri-I TDI has partnered with Takeda Pharmaceutical Company, Ltd., a global research-based pharmaceutical company with a strong record of bringing new medicines to market, to benefit drug discovery work at all three institutions.